Flomics Biotech is a Catalan company that has developed a diagnostic method based on analysis of nucleic acids present in the blood. Through a liquid biopsy, they detect the early phase of complex illnesses such as colorectal cancer, where an early diagnosis doubles the possibilities of survival.
Early diagnosis obtained in a non-invasive manner is a common challenge in the world of biotechnology. That’s why Flomics is committed to the use of RNA molecules, more dynamic and informative than any other existing biomarker on the market. Behind the company are João Curado, Roderic Guigó, Esther Lizano and Luis Korrodi, expert entrepreneurs in computational and molecular biology. Barely a year ago, in 2018, they launched this method which applies machine-learning algorithms. The company commercialises its diagnostic service through blood samples directly with hospitals and private clinics.
They receive samples directly from their own laboratories and return the results through an online cloud platform for the convenience of the medic and the patient. Flomics has been financed directly with own funds to the tune of 100 thousand euros and thanks to a number of public and private subsidies from strategic partners that have helped generate the first data set that shows the potential of the company’s technology.
It has also participated in the IMAGINE IF! by Innovation Forum, and currently in CRAASH! Barcelona, supported by EIT Health, Biocat de Barcelona and CIMIT Boston. As objectives for the next two years, Flomics are seek pilot clients and strategic partners with the aim of obtaining more samples and data, thus boosting the credibility and positioning of the company on the Spanish market. Despite the fact that it is a young company in the development phase, in its first tear they already forecast sales of around 50 thousand euros.